Bristol-Myers Squibb

Bristol-Myers' Opdivo and Janssen PhI candidate to be combined in lung cancer

AbbVie, Bristol-Myers to combine checkpoint inhibitors, Rova-T in cancer trials

China to pip U.S. researchers to the post on first CRISPR trial

Bristol-Myers Squibb buys cancer, rare disease biotech Cormorant

New Gilead hep C combo Epclusa gains FDA approval

BMS nabs a sixth ‘breakthrough’ tag for Opdivo in bladder cancer

Cancer immunotherapy may increase risk of developing rheumatologic disorders: Johns Hopkins study

Incyte shrugs off trial failures with Merck PD-1/epacadostat tie-up

Scancell melanoma trial halt could last a year after drug batch goes bad

Merck-Bristol showdown awaits as Keytruda scores in 1st line NSCLC